Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ContextVision AB (publ) (CONTX.OL)
Stockholm, SE
ContextVision AB (publ), a medical technology enterprise established in Stockholm, Sweden, in 1983, delivers sophisticated software solutions. The firm specializes in image analysis and artificial intelligence, supplying these advanced technologies to original equipment manufacturers (OEMs) across Asia, Europe, and the United States. Their comprehensive product suite is designed to optimize image quality across various medical imaging modalities, including two-dimensional, three-dimensional, and four-dimensional ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Key offerings include: Rivent: Provides superior image quality for a broad spectrum of ultrasound applications such as women's health, general imaging, cardiovascular, and point-of-care. VolarView: An image enhancement software specifically developed for the burgeoning handheld ultrasound market. GOPiCE: A proprietary technology enabling real-time volumetric image enhancement. Altumira/Altumira Plus: A robust platform for digital radiography. An Orthopedic Package: Tailored for specialized orthopedic imaging needs. GOPView MRI2Plus: An advanced solution for MRI image improvement. INIFY Prostate Screening: Offers digital analysis for prostate biopsies.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.92% | +8.14% | +6.29% | +5.38% | -2.11% | -10.36% | -21.68% | -58.01% | -77.72% | +26.53% | -11.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%-18.5% Q1'26: +11.8% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-96.9% Q1'26: +128.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+5.8% Q1'26: +7.4% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+2.8% Q1'26: +2.9% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+5.1% Q1'26: +7.7% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%-1.8% ★ Q1'26: -1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×2.21× ★ Q1'26: 1.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
72.24M
est: 74.96M (-3.6%)
|
81.92M
est: 73.62M (+11.3%)
|
80.51M
est: 81.02M (-0.6%)
|
90.90M
est: 87.16M (+4.3%)
|
95.31M
est: 89.23M (+6.8%)
|
94.75M
est: 102.74M (-7.8%)
|
98.10M
est: 93.32M (+5.1%)
|
117.82M
est: 106.69M (+10.4%)
|
132.60M
est: 135.49M (-2.1%)
|
130.67M
est: 127.89M (+2.2%)
|
106.53M
est: 105.56M (+0.9%)
|
109.57M
109.57M – 109.57M
+3.8% YoY
|
111.78M
111.78M – 111.78M
+2.0% YoY
|
114.00M
114.00M – 114.00M
+2.0% YoY
|
| EBITDA |
11.21M
est: 34.32M (-67.3%)
|
5.99M
est: 33.70M (-82.2%)
|
2.91M
est: 37.09M (-92.2%)
|
5.41M
est: 39.90M (-86.4%)
|
28.27M
est: 40.85M (-30.8%)
|
57.76M
est: 47.03M (+22.8%)
|
55.78M
est: 42.72M (+30.6%)
|
49.92M
est: 48.84M (+2.2%)
|
50.31M
est: 62.03M (-18.9%)
|
40.20M
est: 45.31M (-11.3%)
|
9.81M
est: 37.40M (-73.8%)
|
38.82M
38.82M – 38.82M
+3.8% YoY
|
39.60M
39.60M – 39.60M
+2.0% YoY
|
40.39M
40.39M – 40.39M
+2.0% YoY
|
| EBIT |
6.95M
est: 27.92M (-75.1%)
|
5.77M
est: 27.42M (-79.0%)
|
-1.97M
est: 30.17M (-106.5%)
|
-1.29M
est: 32.46M (-104.0%)
|
10.10M
est: 33.23M (-69.6%)
|
47.76M
est: 38.26M (+24.8%)
|
44.48M
est: 34.75M (+28.0%)
|
41.13M
est: 39.73M (+3.5%)
|
41.48M
est: 50.45M (-17.8%)
|
31.57M
est: 35.45M (-11.0%)
|
3.01M
est: 29.26M (-89.7%)
|
30.37M
30.37M – 30.37M
+3.8% YoY
|
30.99M
30.99M – 30.99M
+2.0% YoY
|
31.60M
31.60M – 31.60M
+2.0% YoY
|
| Net Income |
5.34M
est: 3.43M (+55.4%)
|
4.25M
est: 11.02M (-61.4%)
|
-1.71M
est: 10.57M (-116.1%)
|
-1.18M
est: 5.14M (-123.0%)
|
7.40M
est: 10.26M (-27.9%)
|
12.08M
est: 10.65M (+13.4%)
|
34.88M
est: -4.73M (+837.2%)
|
28.79M
est: 31.99M (-10.0%)
|
32.73M
est: 37.49M (-12.7%)
|
24.68M
est: 27.19M (-9.2%)
|
760.3K
est: 10.60M (-92.8%)
|
11.74M
11.74M – 11.74M
+10.8% YoY
|
12.43M
12.43M – 12.43M
+5.9% YoY
|
13.12M
13.12M – 13.12M
+5.6% YoY
|
| SGA |
18.39M
est: 7.45M (+147.0%)
|
23.37M
est: 7.31M (+219.6%)
|
27.94M
est: 8.05M (+247.2%)
|
33.15M
est: 8.66M (+282.9%)
|
21.44M
est: 8.86M (+141.9%)
|
17.80M
est: 10.20M (+74.4%)
|
9.60M
est: 9.27M (+3.5%)
|
—
est: 10.60M (-100.0%)
|
27.98M
est: 13.46M (+107.9%)
|
—
est: 7.90M (-100.0%)
|
—
est: 6.52M (-100.0%)
|
6.77M
6.77M – 6.77M
+3.8% YoY
|
6.90M
6.90M – 6.90M
+2.0% YoY
|
7.04M
7.04M – 7.04M
+2.0% YoY
|
| EPS |
0.07
est: 0.04 (+55.4%)
|
0.06
est: 0.14 (-61.4%)
|
-0.02
est: 0.14 (-116.2%)
|
-0.02
est: 0.07 (-122.9%)
|
0.10
est: 0.13 (-28.2%)
|
0.16
est: 0.14 (+16.2%)
|
0.45
est: -0.06 (+835.7%)
|
0.37
est: 0.41 (-10.5%)
|
0.42
est: 0.48 (-13.3%)
|
0.32
est: 0.36 (-10.5%)
|
0.01
est: 0.14 (-92.8%)
|
0.15
0.15 – 0.15
+10.8% YoY
|
0.16
0.16 – 0.16
+5.9% YoY
|
0.17
0.17 – 0.17
+5.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gerald Potzsch | Chief Executive Officer | 3M | male |
| Ola Lindblad | Chief Sales & Marketing Officer | 1M | male |
| Martin Hedlund | Co-Founder & Director | 253.0K | male |
| Sven Gunther-Hanssen | Co-Founder & Director | 253.0K | male |
| Katarina Flood | Chief Product & Service Officer | — | female |
| Richard Hallstrom | Chief Financial Officer | — | male |
| Marco Marien Voormolen | Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CONTX.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
